Paraoxonase gene polymorphisms, oxidative stress, and diseases

Journal of Molecular Medicine

Volumn 81, Issue 12, 2003, Pages 766-779

  Li, Hong Liang ^a,b,c   Liu, De Pei ^a,b   Liang, Chih Chuan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

Atherosclerosis; Coronary heart disease; Paraoxonase; Polymorphism; Review

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GENE PRODUCT; ORGANOPHOSPHATE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BIRTH WEIGHT; DNA POLYMORPHISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PATHOLOGY; PHENOTYPE; PREVALENCE; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MULTIGENE FAMILY; OXIDATIVE STRESS; POLYMORPHISM, GENETIC;

EID: 0346095221     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-003-0481-4     Document Type: Review

References (105)

1. Costa LG, Cole TB, Jarvik GP and Furlong CE (2003) Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu Rev Med 54:371-392
2. Costa LG, Furlong CE (2003) Paraoxonase (PON1) in health and disease: basic and clinical aspects. Kluwer Norwell, pp 165-183
3. Mackness B, Durrington PN, Mackness MI (2002) The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 13:357-362
4. Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 144:639-644
5. Ito T, Yasue H, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Kawano H, Ogawa H (2002) Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 110:89-94
6. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M (2002) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:740-745
7. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763-764
8. Worth J (2002) Paraoxonase polymorphisms and organophosphates. Lancet 360:802-803
9. Allebrandt KV, Souza RL, Chautard-Freire-Maia EA (2002) Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 180:151-156
10. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J (2002) Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33:1459-1464
11. Yamada M, Sodeyama N, Itoh Y, Otomo E, Matsushita M, Mizusawa H (2002) No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. Stroke 33:896-900
12. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G (2002) PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 32:9-15
13. Sangvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M (2003) The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun 300:501-506
14. Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, Jokela H, Laakso J, Jaakkola O, Solakivi T, Lehtimaki T (2001) Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 79:449-458
15. Rowles J, Scherer SW, Xi T, Majer M, Nickle DC, Rommans JM, Popov KM, Harris RA, Riebow NL, Xia J (1996) Cloning and characterisation of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human. J Biol Chem 271:22376-22382
16. Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI (2000) Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin Sci (Colch) 98:355-363
17. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442
18. Josse D, Ebel C, Stroebel D, Fontaine A, Borges F, Echalier A, Baud D, Renault F, Le Maire M, Chabrieres E, Masson P (2002) Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J Biol Chem 277:33386-33397
19. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
20. La Du BN (1996) Structural and functional diversity of paraoxonases. Nat Med 2:1186-1187
21. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301-4308
22. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481-488
23. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275:17527-17535
24. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287
25. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484-490
26. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM (2002) Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290:921-927
27. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923-1929
28. Ahmed Z, Babaei S, Maguire GF, Draganov D, Kuksis A, La Du BN, Connelly PW (2003) Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc Res 57:225-231
29. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276:24473-24481
30. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590
31. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2002) Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun 290:391-396
32. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517
33. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE (2002) Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329-1333
34. Arrol S, Mackness MI, Durrington PN (1996) Low density lipoprotein associated with enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med 4:33-48
35. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137:123-137
36. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE (2003) Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357-364
37. Feingold KR, Memon RA, Moser AH (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307-315
38. Aviram M, Rosenblat M, Billecke S (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892-904
39. Ferre N, Camps J, Cabre M (2001) Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997-1000
40. Gonzalvo MC, Gil F, Hernandez AF et al (1997) Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials Chem Biol Interact 105:169-179
41. James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257
42. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76
43. Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598-608
44. Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123-134
45. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-442
46. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-264
47. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197-203
48. Furlong CE, Cole TB, Jarvik GP, Costa LG (2002) Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3:341-348
49. Leviev I, Poirier O, Nicaud V, Evans A, Kee F, Arveiler D, Morrisson C, Cambien F, James RW (2002) High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 161:463-467
50. Leviev I, Kalix B, Brulhart Meynet MC, James RW (2001) The paraoxonase PON1 promoter polymorphism C (-107) T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia 44:1177-1183
51. Leviev I, Righetti A, James RW (2001) Paraoxonase promoter polymorphism T (-107) C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79:457-463
52. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436
53. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84
54. Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516-521
55. James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257
56. Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, Kim SM, Dooley A, Langi S, Hama SY, Navab M, Witztum JL, Fogelman AM (2000) Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 20:1946-1952
57. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM (2001) High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103:2283-2288
58. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106:1127-1132
59. De Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB (2002) Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism 51:1534-1537
60. Freese R, Alfthan G, Jauhiainen M, Basu S, Erlund I, Salminen I, Aro A, Mutanen M (2002) High intakes of vegetables, berries, and apples combined with a high intake of linoleic or oleic acid only slightly affect markers of lipid peroxidation and lipoprotein metabolism in healthy subjects. Am J Clin Nutr 76:950-960
61. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G, Aro A, Kesaniemi YA (2002) Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 132:3012-3017
62. Hegele RA (1999) Paraoxonase genes and disease. Ann Med 31:217-224
63. Leus FR, Zwart M, Kastelein JJ, Voorbij HA (2001) PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154:641-649
64. Ikeda T, Obayashi H, Hasegawa G, Nakamura N, Yoshikawa T, Imamura Y, Koizumi K, Kinoshita S (2001) Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol 132:191-195
65. Fanella S, Harris SB, Young TK, Hanley AJ, Zinman B, Connelly PW, Hegele RA (2000) Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med 38:413-420
66. Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, Lehtimaki T (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11:625-633
67. Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W (2002) Human paraoxonase1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 98:116-122
68. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457
69. Bonafe M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, Pieri C, Marra M, Antonicelli R, Troiano L, Gueresi P, Passeri G, Berardelli M, Paolisso G, Barbieri M, Tesei S, Lisa R, De Benedictis G, Franceschi C (2002) Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 10:292-296
70. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62-66
71. Murphy MM, Vilella E, Ceruelo S, Figuera L, Sanchez M, Camps J, Cuco G, Ferre N, Labad A, Tasevska N, Arija V, Joven J, Fernandez-Ballart J (2002) The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 48:372-375
72. 55 genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
73. James RW, Leviev I, Ruiz J (2000) Promoter polymorphism T (-107) C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49:1390-1393
74. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449
75. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149-157
76. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA (1998) Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139:131-136
77. Gunnarsdottir I, Birgisdottir BE, Thorsdottir I, Gudnason V, Benediktsson R (2002) Size at birth and coronary artery disease in a population with high birth weight. Am J Clin Nutr 76:1290-1294
78. Bhopal R, Fischbacher CM (2002) Many South Asian people probably need pre-diabetes care. BMJ 325:965
79. Cassell PG, Jackson AE, North BV, Evans JC, Syndercombe-Court D, Phillips C, Ramachandran A, Snehalatha C, Gelding SV, Vijayaravaghan S, Curtis D, Hitman GA (2002) Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 51:1622-1628
80. Busch CP, Ramdath DD, Ramsewak S, Hegele RA (1999) Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics 9:351-356
81. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI (2003) Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72:13-22
82. Pan JP, Lai ST, Chiang SC, Chou SC, Chiang AN (2002) The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 65:415-421
83. Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 44:104-107
84. Kao YL, Donaghue K, Chan A, Knight J, Silink A (1998) A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 83:2589-2592
85. Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657-660
86. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598-602
87. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI (2000) Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Colch) 98:355-363
88. Araki S, Makita Y, Canani L, Ng D, Warram JH, Krolewski AS (2000) Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type I diabetes mellitus. Diabetologia 43:1540-1543
89. Canani LH, Araki S, Warram JH, Krolewski AS (2001) Comment-to: Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in type II diabetes. Diabetologia 44:104-107. Diabetologia 44:1062-1064
90. Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M (2002) Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 19:212-215
91. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L (2002) Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord 17:764-766
92. Akhmedova SN, Yakimovsky AK, Schwartz EI (2001) Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 184:179-182
93. Konda I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 806:271-273
94. Wang J, Liu Z (2000) No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Mov Disord 15:1265-1267
95. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP (2002) Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci 977:239-244
96. Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J (2002) Codon 311 (Cys→-Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psychiatry 7:110-112
97. Zuliani G, Ble' A, Zanca R, Munari MR, Zurlo A, Vavalle C, Atti AR, Fellin R (2001) Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. Acta Neurol Scand 103:304-308
98. Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O'Neill BJ, Bata IR, Johnstone DE, Title LM (2002) Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 35:205-209
99. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66-73
100. Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J (2002) Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321:165-168
101. Barbieri M, Bonafe M, Marfella R, Ragno E, Giugliano D, Franceschi C, Paolisso G (2002) LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab 87:222-225
102. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 118:477-448
103. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442
104. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542-547
105. Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20-24